BI

BVF Inc Portfolio holdings

AUM $2.97B
1-Year Est. Return 167.08%
This Fund
S&P 500
This Quarter Est. Return
1 Year Est. Return
+167.08%
3 Year Est. Return
5 Year Est. Return
10 Year Est. Return
AUM
$2.97B
AUM Growth
+$504M
Cap. Flow
Cap. Flow %
Top 10 Hldgs %
Holding
48
New
Increased
Reduced
Closed

Top Buys

1
+$65.6M
2
+$54.9M
3
+$40.6M
4
STOK icon
Stoke Therapeutics
STOK
+$18.3M
5
CBIO
Crescent Biopharma
CBIO
+$17.3M

Top Sells

1
+$170M
2
+$135M
3
+$61.6M
4
SEPN
Septerna Inc
SEPN
+$54.8M
5
RVMD icon
Revolution Medicines
RVMD
+$40.5M

Sector Composition

1 Healthcare 99.92%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
FDMT icon
26
4D Molecular Therapeutics
FDMT
$499M
$34.7M 1.17%
4,629,289
CBIO
27
Crescent Biopharma
CBIO
$607M
$32.6M 1.1%
2,748,763
+1,360,900
FHTX icon
28
Foghorn Therapeutics
FHTX
$286M
$28.6M 0.96%
5,302,000
RPTX
29
DELISTED
Repare Therapeutics
RPTX
$26.9M 0.9%
10,333,600
AVTX icon
30
Avalo Therapeutics
AVTX
$304M
$24.6M 0.83%
1,355,257
+1
PEPG icon
31
PepGen
PEPG
$119M
$12.5M 0.42%
1,915,000
ELDN icon
32
Eledon Pharmaceuticals
ELDN
$250M
$9.5M 0.32%
6,293,282
XFOR icon
33
X4 Pharmaceuticals
XFOR
$394M
$8.93M 0.3%
2,233,742
AXSM icon
34
Axsome Therapeutics
AXSM
$9.42B
$8.36M 0.28%
45,757
-441,000
MOLN
35
Molecular Partners
MOLN
$157M
$5.82M 0.2%
1,353,968
IMA
36
ImageneBio Inc
IMA
$63.2M
$5.53M 0.19%
802,102
TCRX icon
37
TScan Therapeutics
TCRX
$60.9M
$5.23M 0.18%
5,226,074
TENX icon
38
Tenax Therapeutics
TENX
$241M
$4.14M 0.14%
339,549
IMUX icon
39
Immunic
IMUX
$145M
$4.08M 0.14%
7,652,972
IVA
40
Inventiva
IVA
$1.19B
$3.19M 0.11%
686,040
ENGNW icon
41
enGene Therapeutics Inc. Warrants
ENGNW
$25M
$2.4M 0.08%
945,402
CDTX
42
DELISTED
Cidara Therapeutics
CDTX
– –
-1,414,165
CELC icon
43
Celcuity
CELC
$5.97B
– –
-658,421
EPIX
44
DELISTED
ESSA Pharma
EPIX
– –
-11,668,473
FBRX icon
45
Forte Biosciences
FBRX
$434M
– –
-65,350
NCEL
46
NewcelX Ltd
NCEL
$11.4M
– –
-14,368
PTGX icon
47
Protagonist Therapeutics
PTGX
$6.73B
– –
-2,560,916
SABS icon
48
SAB Biotherapeutics
SABS
$285M
– –
-932,697
1
2